Stay updated on Pembrolizumab for Small Bowel Adenocarcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Small Bowel Adenocarcinoma Clinical Trial page.

Latest updates to the Pembrolizumab for Small Bowel Adenocarcinoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe clinical trial record for pembrolizumab in advanced small bowel adenocarcinoma is displayed, with study details, participant criteria, locations, outcome measures, and a study protocol document.SummaryDifference53%

- Check16 days agoChange DetectedThe site footer now displays revision v3.8.0 instead of v3.7.2. The study record still shows a 403 Forbidden error.SummaryDifference0.2%

- Check23 days agoChange DetectedA sitewide NIH announcement banner appears above the study record, describing a terminology transition from “Artificial Intelligence” to “Super Intelligence.” The study content remains a 403 error page.SummaryDifference1%

- Check30 days agoChange DetectedThe footer revision identifier changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check37 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1. The page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the expected study record content. This indicates a permission issue rather than an update to the study information.SummaryDifference19%

Stay in the know with updates to Pembrolizumab for Small Bowel Adenocarcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Small Bowel Adenocarcinoma Clinical Trial page.